Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy

Summary

The study is planned to provide expanded access treatment to subjects with narcolepsy who have completed the 2-week treatment phase and follow-up in study CTP2S13031H3 (NCT04072380), and in instances when the investigator as well as the subject believe that the benefits outweigh the risks to continue the treatment with SUVN-G3031.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications